tirzepatide glp1 and gip is a first-in-class dual agonist targeting both GLP-1 receptors, offering a powerful and synergistic approach to glycaemic control and weight management., By acting on multiple Tirzepatide — Weight Loss |

Key efficacy results: - Up to 12.2% weight loss from baseline (26.6 lbs) at the highest dose - Up to 10.9% placebo-adjusted weight loss - Statistically significant, dose-dependent weight loss across all dose cohorts - Weight loss was progressive from Week 1 through Week 13 with no plateau observed - Significant differences versus placebo were observed for all doses above 15 mg starting at Week 1 Why "no plateau" matters: Most GLP-1 drugs show a weight loss plateau at some point the body adapts and weight loss slows

Samar Khalek, FNP-BC Board-Certified Family Nurse Practitioner Samar is a board-certified family nurse practitioner who supports clients throughout their GLP-1-based weight-loss journey with thoughtful, patient-focused care

Debra Houry, acting deputy director of the CDC, in a recent press release

Without a specialized delivery technology like SNAC (under patent by Novo), the drug cannot survive digestion to work in the body

While the sublingual route is pharmacologically plausible for some peptide absorption, the lack of data means effectiveness claims are unsubstantiated